<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4772">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01768702</url>
  </required_header>
  <id_info>
    <org_study_id>C3BS-C-11-01</org_study_id>
    <secondary_id>2011-001117-13</secondary_id>
    <nct_id>NCT01768702</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.</brief_title>
  <acronym>CHART-1</acronym>
  <official_title>Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardio3 BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardio3 BioSciences</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the safety and efficacy of C3BS-CQR-1 by comparing the overall response to
      standard of care and C3BS-CQR-1 relative to standard of care and a sham procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy between groups post-index procedure</measure>
    <time_frame>39 weeks post-index</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change between groups from baseline and 39 weeks in a hierarchical composite outcome comprising, from most to least severe outcome, days to death from any cause, number of worsening of heart failure events, change in score for the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (10-point deterioration, no meaningful change,10-point improvement), change in six-minute walk distance (40-m deterioration, no meaningful change, 40-m improvement) and change in left ventricular end systolic volume (15-mL deterioration, no meaningful change, 15-mL improvement), and left ventricular ejection fraction (4% absolute deterioration, no meaningful change, 4% absolute improvement).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy and safety between groups post-index procedure</measure>
    <time_frame>52 and 104 weeks post-index</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety: Number and cause of deaths and re-admissions, number of cardiac transplantations, number of myocardial infarctions, number of strokes. Incidence of  serious adverse events (AE) through week 104 and non-serious AEs (through week 52).
Efficacy: Time to all cause mortality, time to worsening of heart failure, and time to aborted sudden death through week 52.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy and safety between groups post-index procedure</measure>
    <time_frame>39 and 52 weeks post-index</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to all cause mortality, time to cardiovascular mortality, and rate of worsening heart failure requiring outpatient IV therapy for heart failure or readmission for heart failure, and others.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham, no injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3BS-CQR-1 Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of C3BS-CQR-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection of C3BS-CQR-1</intervention_name>
    <description>Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.</description>
    <arm_group_label>C3BS-CQR-1 Treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sham, no injection</intervention_name>
    <description>Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible patients must meet all of the following inclusion criteria:

          1. Age ≥ 18 and &lt; 80 years.

          2. Systolic dysfunction with left ventricular ejection fraction (LVEF) ≤ 35% as assessed
             by echocardiography.

          3. Ischemic heart failure without known need for revascularization.

          4. Total MLHFQ score &gt; 30.

          5. Ability to perform a 6 minute walk test &gt; 100 m and ≤ 400 m.

          6. History of hospitalization for heart failure (HF) within 12 months prior to screening
             or treatment in an outpatient clinic with intravenous vasoactive therapy (including
             vasodilators, positive inotropic agents and vasopressors) or diuretics for worsening
             Heart Failure within 12 months prior to screening.

          7. Be or must have been within the previous 12 months in New York Heart Association
             (NYHA) Class III or IV or Interagency Registry for Mechanically Assisted Circulatory
             Support (INTERMACS) class 4, 5, 6 or 7, and at the time of inclusion, must be at
             least in NYHA Class II or greater.

          8. Use of ACE inhibitor and/or angiotensin receptor blocker (ARB); and beta blocker, for
             at least 3 months prior to screening visit, unless intolerant or contraindicated.

          9. Stable dosing of ACE inhibitor, angiotensin receptor blocker , beta blocker,
             aldosterone blocker,and diuretics for at least one month prior to screening visit,
             defined as ≤50% change in total dose of each agent.

         10. Willing and able to give written informed consent.

        Exclusion Criteria (summarized):

        Eligible patients must meet none of the following exclusion criteria:

          1. Women who are pregnant, confirmed by a positive urine or serum human chorionic
             gonadotropin laboratory test at screening.

          2. Women of child-bearing potential without a negative serum or urine pregnancy test at
             screening.

          3. Men refusing to exercise a reliable form of contraception.

          4. Myocardial infarction, unstable angina or percutaneous coronary intervention (PCI)
             within 90 days prior to screening, or coronary artery bypass graft surgery within 180
             days prior to screening.

          5. Patient on a cardiac transplant list or previously received any solid organ
             transplant.

          6. Previously underwent cardiac surgery with remodeling procedure, left ventricular
             assist device placement or cardiomyoplasty. This exclusion does not apply to patients
             who underwent ventricularplasty without placement device more than one year ago.

          7. Patient has undergone cardiac resynchronization therapy within 6 months prior to
             screening.

          8. Severe uncontrolled HF requiring need for intensive intravenous diuretics or
             inotropic support within 1 month prior to screening.

          9. Inability to perform a 6 minute walk test due to physical limitations other than HF
             including:

               1. Severe peripheral vascular disease

               2. Severe pulmonary disease or chronic obstructive pulmonary disease limiting
                  exercise

               3. Orthopedic limitations, severe muscular diseases, any other joint or muscular
                  disease or neurological disorder (such as an old stroke or neuropathy) limiting
                  the ability to walk for 6 minutes.

         10. Dependence on chronic oral steroid therapy.

         11. Stroke or transient ischemic attack leading to limitations in lower extremities or
             occurring within 180 days prior to screening.

         12. Active myocarditis, constrictive pericarditis, restrictive, hypertrophic or
             congenital cardiomyopathy.

         13. BMI &lt; 19 or &gt; 45.

         14. Left ventricular thrombus.

         15. Left ventricular (LV) wall thickness &lt; 8mm visualized in more than 50% of LV, and
             defined as a &quot;LV no-go zone&quot;.

         16. LV aneurysm or candidate for surgical aneurysmectomy.

         17. Sustained ventricular tachycardia or ventricular fibrillation which led to automatic
             implantable cardioverter/defibrillator (AICD) therapy (shock) within 3 months prior
             to screening.

         18. Primary significant organic valvular heart disease.

         19. Moderate to severe aortic valve disease precluding catheter entry into the LV.

         20. Mechanical prosthetic valve in aortic or mitral position.

         21. Chronic infection or active malignancy.

         22. Patient has compromised renal function as reflected by a serum creatinine level &gt;3.0
             mg/dL (&gt;0.265 mmol/L) or is currently on dialysis.

         23. Hematocrit &lt; 28%.

         24. Atherosclerosis and/or tortuosity of the aorta, iliac or femoral arteries of a degree
             that could impede or preclude the safe retrograde passage of the delivery catheter.

         25. Chronic immunosuppressive therapy due to inflammatory or systemic disease.

         26. Patient tested positive for HIV 1 or 2, Hepatitis B or C, human T-cell lymphotrophic
             virus  (HTLV) 1 or 2 (if required by regulations) or syphilis.

         27. Exposure to any previous experimental cell or angiogenic therapy and/or myocardial
             laser therapy and/or therapy with another investigational drug within 60 days prior
             to screening or enrollment in any concurrent study that may confound the results of
             this study.

         28. Known drug or alcohol dependence or any other factors which will interfere with the
             study conduct or interpretation of the results or in the opinion of the investigator
             are not suitable to participate.

         29. Any illness other than congestive heart failure which might reduce life expectancy to
             less than 2 years from screening.

         30. Known and relevant allergies and/or hypersensitivities to Dextran or other plasma
             volume expanders to include Gentran, Hyskon and Macrodex.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Terzic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic, Division of Cardiovascular Diseases, Rochester (MN, USA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jozef Bartunek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>OLV Ziekenhuis Aalst (Belgium)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Homsy, MD</last_name>
    <phone>+32 10 39 41 00</phone>
    <email>chomsy@c3bs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>OLV Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Vanderheyden, MD</last_name>
      <phone>+32 53 724435</phone>
      <email>Marc.Vanderheyden@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Marc Vanderheyden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Civil de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariouch Dolatabadi, MD</last_name>
      <phone>+32 71 920668</phone>
      <email>dariouch.dolatabadi@chu-charleroi.be</email>
    </contact>
    <investigator>
      <last_name>Dariouch Dolatabadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Dens, MD</last_name>
      <phone>+32 89 327160</phone>
      <email>jo.dens@zol.be</email>
    </contact>
    <investigator>
      <last_name>Joseph Dens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Legrand, MD</last_name>
      <phone>+32 4 3667854</phone>
      <email>vlegrand@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Victor Legrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Guedes, MD</last_name>
      <phone>+32 81 4236 28</phone>
      <email>Antoine.Guedes@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Antoine Guedes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Országos Kardiológiai Intézet - Felnőtt Kardiológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Péter Andréka, MD Prof</last_name>
      <phone>+36 70 382 02 70</phone>
      <email>Andreka.peter@kardio.hu</email>
    </contact>
    <investigator>
      <last_name>Péter Andréka, MD Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MH Egészségügyi Központ Kardiológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noemi Nyolczas, MD PhD</last_name>
      <phone>+36 20 945 12 01</phone>
      <email>nyolczasnoemi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Noemi Nyolczas, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem - Városmajori Szív- és Érgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Béla Merkely, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Béla Merkely, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem Klinikai Központ - Szívgyógyászati Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iván G. Horváth, MD, PhD</last_name>
      <phone>+36 72 536 000 35601</phone>
      <email>ivan.g.horvath@aok.pte.hu</email>
    </contact>
    <investigator>
      <last_name>Iván G. Horváth, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center - Cardiology Unit</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amos Katz, MD, Prof</last_name>
      <phone>+972 8 674 58 70</phone>
      <email>amosk@barzi.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Amos Katz, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nazareth Hospital EMMS</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhamad Omary, MD</last_name>
      <phone>+372 54 66 93 464</phone>
      <email>mohamedomary@nazhosp.com</email>
    </contact>
    <investigator>
      <last_name>Muhamad Omary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center - Heart Institute</name>
      <address>
        <city>Safed</city>
        <zip>13110</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Majdi Halabi, MD</last_name>
      <phone>+972 4 682 88 44</phone>
      <email>majdi.h@ziv.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Majdi Halabi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Biegański Hospital</name>
      <address>
        <city>Łódź</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaroslaw Kasprazak, MD Prof</last_name>
      <phone>+48 42 653 99 09</phone>
      <email>kasprzak@ptkardio.pl</email>
    </contact>
    <investigator>
      <last_name>Jaroslaw Kasprazak, MD Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Cardiology Clinic</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petar Seferovic, MD</last_name>
      <phone>+381 113614738</phone>
      <email>seferovic@med.bg.ac.rs</email>
    </contact>
    <investigator>
      <last_name>Petar Seferovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia - Cardiology Clinic</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Branko Beleslin, MD Prof</last_name>
      <phone>+381 11 36 13 653</phone>
      <email>branko.beleslin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Branko Beleslin, MD Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara - Cardiology Clinic</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Arandjelovic, MD Prof</last_name>
      <phone>+381 60 88 39 333</phone>
      <email>drarandjelovic@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Aleksandra Arandjelovic, MD Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria - Campus de Teatinos s/n</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Maria Hernandez Garcia, MD</last_name>
      <phone>+34 95 103 23 89</phone>
      <email>jmhg@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Jose Maria Hernandez Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>December 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Heart Failure of Ischemic Origin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
